Prestige Consumer Healthcare (NYSE:PBH) Shares Gap Up – Time to Buy?

Prestige Consumer Healthcare Inc. (NYSE:PBH)’s share price gapped up prior to trading on Friday . The stock had previously closed at $60.06, but opened at $61.95. Prestige Consumer Healthcare shares last traded at $61.4020, with a volume of 168,459 shares.

Analysts Set New Price Targets

A number of analysts have recently weighed in on PBH shares. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Jefferies Financial Group reduced their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Stock Up 1.3%

The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. The firm has a market cap of $2.88 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 1.91 and a beta of 0.41. The business’s 50 day moving average price is $65.89 and its 200 day moving average price is $63.36.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm had revenue of $283.44 million for the quarter, compared to analysts’ expectations of $286.93 million. During the same period last year, the company posted $1.22 earnings per share. The business’s quarterly revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the sale, the vice president directly owned 41,048 shares in the company, valued at $2,706,294.64. This trade represents a 2.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its stake in shares of Prestige Consumer Healthcare by 4.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock worth $100,893,000 after acquiring an additional 70,376 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Prestige Consumer Healthcare during the 3rd quarter worth $1,890,000. AXQ Capital LP acquired a new stake in Prestige Consumer Healthcare during the 2nd quarter worth $694,000. Tributary Capital Management LLC raised its position in shares of Prestige Consumer Healthcare by 157.3% in the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after buying an additional 231,969 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Prestige Consumer Healthcare by 30.1% in the third quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock worth $28,656,000 after buying an additional 106,224 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).